ClinicalTrials.gg
Not yet recruitingNCT07847814Updated Oct 9, 2026

Evaluation of F&P Mask, US, 2026

An interventional study of F&P Mask in Chronic Respiratory Conditions and Obstructive Sleep Apnea (OSA), sponsored by Fisher and Paykel Healthcare. Not yet recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Treatment

Updated Oct 9, 2026Study contact changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare — 2 open to participants now, 2 under way, none of them phase 3. Sleep Apnea, Obstructive · Fisher and Paykel Healthcare.

Planned enrollment
14th of 60
45 · median 34
Started
2026
with 1 other
No phase
58 of 63
2 open now
Registered
63rd of 63
by date

Among the 63 studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare, this one is the 14th largest by planned enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2026, is one of 58 with no phase, and was the 63rd registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

2 of the 63 studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Sleep Apnea, Obstructive by Fisher and Paykel Healthcare, or all of them as a file.
02

Study summary

This clinical investigation is designed to validate and confirm the overall performance, safety, usability, reliability, and acceptability of the F\&P mask in a home environment.

03

Conditions studied

  • Chronic Respiratory Conditions
  • Obstructive Sleep Apnea (OSA)
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ≥22 years of age
  • Weigh ≥66 pounds
  • Have been prescribed PAP/NIV therapy by a physician
  • Are an existing PAPNIV mask user with ≥3 months of use prior to enrolment in the clinical investigation
  • Are compliant with PAP/NIV therapy for ≥4 hours per night for ≥70% of nights for a 14-day period within 30 days prior to enrolment in the clinical investigation
  • Are fluent in spoken and written English
  • Possess the capacity to provide

Exclusion criteria

Exclusion Criteria:

  • Possess, or suffer from, anatomical or physiological conditions which make PAP/NIV therapy inappropriate
  • Are required to use PAP/NIV therapy for >12 hours per day or for extensive periods, not including sleep or naps
  • Are trying to get pregnant, are pregnant, or think they may be pregnant
  • Have an IPAP pressure of >30 cmH2O if on BPAP
  • Use a PAP/NIV therapy device for the delivery of medicines, except supplemental O2
  • Use a PAP/NIV therapy device that does not possess data recording capabilities to capture AHI and a numerical indicator of leak that is accessible to the clinical investigation site
  • Have a history of light-induced seizures (for optional anthropometric scan only)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Other
    Intervention

    Single-arm, non-randomised, open-label

    Device: F&P Mask

Interventions

  • DeviceF&P Mask

    PAP/NIV Therapy Mask

06

What researchers measure

Primary outcomes

  1. Therapeutic Efficacy

    Determined by Apnea-Hypopnea Index (AHI) recorded on PAP therapy machines after 14 days of use. The Apnea-Hypopnea index (AHI) is the sum of the apneas and hypopneas divided by the hours of sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \>= 30/h = severe AHI is measured by dividing the total number of recorded apneas (complete breathing stops) and hypopneas (shallow breathing episodes) by the total number of hours a person slept during an overnight sleep study or using a PAP device. Higher AHI values represent worse outcomes. There is no maximum theoretical index score.

    Time frame: Baseline and 14±5 days

  2. Epworth Sleepiness Scale

    All relevant time points used in the calculation in the Time Frame (e.g., baseline and 14±5 days). Note: change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 14±5 days minus value at baseline). Change between two time points is reported. Scale range: 0 (minimum score) to 24 (maximum score) (higher scores represent worse outcomes)

    Time frame: 14±5 days

  3. Patient and Clinical Global Impression (PGI/CGI)

    Determined by Patient Global Impression (PGI) and Clinical Global Impression (CGI) assessments completed at baseline and Day 14. Baseline symptom severity is assessed using a 6-point scale (1 = No symptoms to 6 = Very severe symptoms). Change from baseline is assessed using a 7-point scale (1 = Very much better to 7 = Very much worse; 4 = No change). Higher severity scores indicate worse symptoms. For change assessments, lower scores indicate improvement and higher scores indicate worsening. PGI is completed by the patient and CGI is completed by the investigator/clinician.

    Time frame: Baseline and 14±5 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for May 2027, 6 months later.

Of 116 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 6 months is below that.

Counting every sponsor, half of 624 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartEst.
Oct 26, 2026
Primary completionEst.
May 14, 2027
CompletionEst.
Jul 14, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: S•••@fphcare.com · •••3912→c•••@fphcare.co.nz · •••6485. See the current contact
Oct 9, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Oct 9, 2026
    Contact Study contact changed: S•••@fphcare.com · •••3912→c•••@fphcare.co.nz · •••6485. See the current contact
    + 1 other change: verification date
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847814
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
May 14, 2027 (estimated)
Completion
Jul 14, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Clinical Research Scientist
Contact
cpap.trial@fphcare.co.nz
+6421436485

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion